Version 1
: Received: 27 June 2024 / Approved: 27 June 2024 / Online: 28 June 2024 (04:37:23 CEST)
Version 2
: Received: 19 August 2024 / Approved: 20 August 2024 / Online: 21 August 2024 (10:48:08 CEST)
How to cite:
Justiz-Vaillant, A.; Arozarena-Fundora, R.; Gopaul, D.; Soodeen, S.; Thompson, R.; Asin-Milan, O.; Unakal, C.; Kurhade, A. Unraveling the Immune Response Dynamics of Leishmaniasis: Insights, Challenges, and Vaccine Development. Preprints2024, 2024061935. https://doi.org/10.20944/preprints202406.1935.v2
Justiz-Vaillant, A.; Arozarena-Fundora, R.; Gopaul, D.; Soodeen, S.; Thompson, R.; Asin-Milan, O.; Unakal, C.; Kurhade, A. Unraveling the Immune Response Dynamics of Leishmaniasis: Insights, Challenges, and Vaccine Development. Preprints 2024, 2024061935. https://doi.org/10.20944/preprints202406.1935.v2
Justiz-Vaillant, A.; Arozarena-Fundora, R.; Gopaul, D.; Soodeen, S.; Thompson, R.; Asin-Milan, O.; Unakal, C.; Kurhade, A. Unraveling the Immune Response Dynamics of Leishmaniasis: Insights, Challenges, and Vaccine Development. Preprints2024, 2024061935. https://doi.org/10.20944/preprints202406.1935.v2
APA Style
Justiz-Vaillant, A., Arozarena-Fundora, R., Gopaul, D., Soodeen, S., Thompson, R., Asin-Milan, O., Unakal, C., & Kurhade, A. (2024). Unraveling the Immune Response Dynamics of Leishmaniasis: Insights, Challenges, and Vaccine Development. Preprints. https://doi.org/10.20944/preprints202406.1935.v2
Chicago/Turabian Style
Justiz-Vaillant, A., Chandrashekhar Unakal and Arvind Kurhade. 2024 "Unraveling the Immune Response Dynamics of Leishmaniasis: Insights, Challenges, and Vaccine Development" Preprints. https://doi.org/10.20944/preprints202406.1935.v2
Abstract
Leishmaniasis, comprising cutaneous and mucocutaneous forms, is a parasitic disease caused by Leishmania species via sandfly bites, leading to skin ulcers and mucosal damage. Traditional treatments include antiparasitic drugs such as pentavalent antimonials, amphotericin B, and miltefosine, with immunotherapy and chemotherapy being explored for enhanced efficacy and reduced relapse. Mucocutaneous leishmaniasis (ML) balances IFN-γ and IL-10, affecting severity, while cutaneous leishmaniasis (CL) shows varied IFN-γ/IL-10 ratios influencing prognosis. Cytokines and chemokines are diagnostic and prognostic markers in CL. Research into neutrophils and the NLRP3 inflammasome informs Th1/Th2 response regulation. Live attenuated LdCen-/- parasites and genetically modified vaccines show promise, with miR-21 as a potential efficacy biomarker. Understanding cytokine networks is crucial for new treatment strategies.
Biology and Life Sciences, Immunology and Microbiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
